Kawakami K, Atarashi S, Kimura Y, Takemura M, Hayakawa I
New Product Research Laboratories I, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.
Chem Pharm Bull (Tokyo). 1998 Nov;46(11):1710-5. doi: 10.1248/cpb.46.1710.
A series of novel LVFX (7) analogues bearing 4,4-dialkyl-3-aminopyrrolidines at the C-10 position of pyridobenzoxazine was synthesized and their antibacterial activities, pharmacokinetics and acute toxicities in animals were evaluated. Non-alkylated pyrrolidine derivative 26a showed greater activity than LVFX (7) against gram-positive and gram-negative bacteria including Pseudomonas aeruginosa, but 26a possessed high acute toxicity in mice and unfavorable pharmacokinetics in rats. When compared with 26a, 4,4-dialkylated derivatives 26c, e.g. showed more potent activity against gram-positive bacteria along with an improvement of pharmacokinetics and reduction of acute toxicity. Increases in lipophilicity by alkylation on the pyrrolidine ring resulted in a good influence on the above profiles.
